Loading
companiesCompany
Ranok Therapeutics (Hangzhou)
Ranok Therapeutics (Hangzhou) is a China-based biotechnology company running 2 late-stage cancer trials of RNK08954-01 and RNK05047 in sarcomas and diffuse large B-cell lymphoma.
Also called: Ranok Therapeutics (Hangzhou) Co., Ltd.Ranok Therapuetics Co. Ltd.
Overview
Ranok Therapeutics (Hangzhou), based in Hangzhou, China, is a biotechnology company. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials, testing RNK08954-01 and RNK05047 in sarcomas and diffuse large B-cell lymphoma. The largest, NCT06667544 (A Study of RNK08954 in Subjects With Advanced Solid Tumours With KRAS ((Kirsten Rat Sarcoma) G12D Mutation), plans to enrol 152 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.
Headquarters
Hangzhou, CN
Scorecard
All companies#485of 1244 companies, score 5
- phase 1/2 +1
- modalities +2
- registry trials +2
0 approved, 0 in phase 3, 1 earlier, 0 targets, 1 registry studies. Formula on the scorecards page.
Type
Website
Phase 2Targeted protein degrader
RNK05047 is a targeted protein degrader from Ranok Therapeutics (Hangzhou) Co., Ltd., in registered phase 2 trials for metastatic cancer.
cancers
drugs
Phase 2Targeted protein degrader
trials
A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)A Study of RNK08954 in Subjects With Advanced Solid Tumors With KRAS ((Kirsten Rat Sarcoma) G12D MutationIN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Solid Tumors